At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO-CONTROLLED STUDY OF PF-04171327 IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
In Brief
A Phase 2 clinical trial evaluating PF-04171327 10 mg, Prednisone Placebo, and 4 other interventions for Rheumatoid Arthritis. Completed, enrolled 86 participants across 41 sites in 13 countries.
Detailed Summary
This study will investigate the safety and efficacy of an investigational drug, PF-04171327 on the signs and symptoms of rheumatoid arthritis in patients that require glucocorticoids while on background methotrexate. This study will also look at the response of chemical and biological markers in rheumatoid arthritis patients. Lastly, this study will measure the PK (amount of drug in the blood) of methotrexate while patients may be taking PF-04171327.
Study Details
Timeline
Interventions
PF-04171327 10 mg tablet every day for 14 days
Placebo for Prednisone 5 mg tablet every day for 14 days
PF-04171327 25 mg tablet every day for 14 days
Placebo for Prednisone 5 mg tablet every day for 14 days
Prednisone 5 mg tablet every day for 14 days
Placebo for PF-04171327 every day for 14 days
Placebo tablet every day for 14 days
Placebo tablet every day for 14 days